Nikhil C. Munshi

95.6k total citations · 10 hit papers
799 papers, 40.1k citations indexed

About

Nikhil C. Munshi is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Nikhil C. Munshi has authored 799 papers receiving a total of 40.1k indexed citations (citations by other indexed papers that have themselves been cited), including 556 papers in Hematology, 471 papers in Molecular Biology and 310 papers in Oncology. Recurrent topics in Nikhil C. Munshi's work include Multiple Myeloma Research and Treatments (541 papers), Protein Degradation and Inhibitors (193 papers) and Peptidase Inhibition and Analysis (104 papers). Nikhil C. Munshi is often cited by papers focused on Multiple Myeloma Research and Treatments (541 papers), Protein Degradation and Inhibitors (193 papers) and Peptidase Inhibition and Analysis (104 papers). Nikhil C. Munshi collaborates with scholars based in United States, France and Italy. Nikhil C. Munshi's co-authors include Kenneth C. Anderson, Paul G. Richardson, Teru Hideshima, Dharminder Chauhan, Constantine S. Mitsiades, Nicholas Mitsiades, Bart Barlogie, Yu‐Tzu Tai, Noopur Raje and Robert Schlossman and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Nikhil C. Munshi

775 papers receiving 39.4k citations

Hit Papers

Antitumor Activity of Thalidomide in Refractory Multiple ... 1999 2026 2008 2017 1999 2013 2001 2002 2002 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
    1999 2.0k citations Nikhil C. Munshi, David S. Siegel et al. profile →
  2. Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
    2013 1.3k citations Jan Krönke, Namrata D. Udeshi et al. Science profile →
  3. Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer
    2001 1.2k citations Nikhil C. Munshi et al. profile →
  4. NF-κB as a Therapeutic Target in Multiple Myeloma
    2002 752 citations Teru Hideshima, Dharminder Chauhan et al. profile →
  5. Molecular sequelae of proteasome inhibition in human multiple myeloma cells
    2002 597 citations Nicholas Mitsiades, Dharminder Chauhan et al. profile →
  6. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
    2003 575 citations Nicholas Mitsiades, Constantine S. Mitsiades et al. Blood profile →
  7. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
    2002 544 citations Nicholas Mitsiades, Constantine S. Mitsiades et al. Blood profile →
  8. IMWG consensus on risk stratification in multiple myeloma
    2013 413 citations Nikhil C. Munshi, Pieter Sonneveld et al. profile →
  9. Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
    2014 375 citations Yu‐Tzu Tai, Chirag Acharya et al. Blood profile →
  10. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
    2021 236 citations Mehmet Samur, Mariateresa Fulciniti et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nikhil C. Munshi United States 106 25.2k 21.5k 16.7k 6.1k 3.8k 799 40.1k
Paul G. Richardson United States 116 33.9k 1.3× 32.3k 1.5× 22.5k 1.4× 5.9k 1.0× 3.4k 0.9× 1.1k 51.8k
Teru Hideshima United States 100 24.6k 1.0× 17.5k 0.8× 13.3k 0.8× 4.6k 0.8× 3.2k 0.9× 472 34.9k
Bart Barlogie United States 109 24.5k 1.0× 30.7k 1.4× 18.3k 1.1× 4.0k 0.7× 2.3k 0.6× 704 42.4k
Michael Andreeff United States 112 25.9k 1.0× 16.0k 0.7× 13.6k 0.8× 7.1k 1.2× 7.3k 1.9× 1.0k 48.1k
Shaji Kumar United States 89 22.8k 0.9× 23.4k 1.1× 14.0k 0.8× 2.7k 0.4× 1.4k 0.4× 1.0k 35.0k
Philippe Moreau France 89 17.9k 0.7× 19.7k 0.9× 14.4k 0.9× 3.5k 0.6× 1.1k 0.3× 1.0k 32.4k
Francis J. Giles United States 105 15.0k 0.6× 20.4k 1.0× 9.3k 0.6× 4.6k 0.8× 2.8k 0.7× 786 41.9k
Bob Löwenberg Netherlands 89 14.3k 0.6× 23.5k 1.1× 8.0k 0.5× 5.4k 0.9× 2.8k 0.7× 534 35.9k
Elihu H. Estey United States 100 16.0k 0.6× 27.6k 1.3× 8.6k 0.5× 4.1k 0.7× 2.4k 0.6× 687 39.7k
Angela Dispenzieri United States 106 31.7k 1.3× 25.5k 1.2× 15.6k 0.9× 2.6k 0.4× 893 0.2× 976 47.8k

Countries citing papers authored by Nikhil C. Munshi

Since Specialization
Citations

This map shows the geographic impact of Nikhil C. Munshi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nikhil C. Munshi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nikhil C. Munshi more than expected).

Fields of papers citing papers by Nikhil C. Munshi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nikhil C. Munshi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nikhil C. Munshi. The network helps show where Nikhil C. Munshi may publish in the future.

Co-authorship network of co-authors of Nikhil C. Munshi

This figure shows the co-authorship network connecting the top 25 collaborators of Nikhil C. Munshi. A scholar is included among the top collaborators of Nikhil C. Munshi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nikhil C. Munshi. Nikhil C. Munshi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kumar, Subodh, Srikanth Talluri, Leutz Buon, et al.. (2023). ABL1 kinase plays an important role in spontaneous and chemotherapy-induced genomic instability in multiple myeloma. Blood. 143(11). 996–1005. 3 indexed citations
2.
Gullà, Annamaria, Eugenio Morelli, Mehmet Samur, et al.. (2021). Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation. Blood Cancer Discovery. 2(5). 468–483. 92 indexed citations
3.
Xing, Lijie, Su Wang, Jiye Liu, et al.. (2021). BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression. Clinical Cancer Research. 27(19). 5376–5388. 22 indexed citations
4.
Lin, Liang, Lijie Xing, Chirag Acharya, et al.. (2017). CD8+ Anti-BCMA mRNA CAR T-Cells Effectively Kill Human Multiple Myeloma Cells In Vitro and In Vivo. Blood. 130. 3067–3067. 6 indexed citations
5.
6.
Das, Deepika Sharma, Abhishek Das, Arghya Ray, et al.. (2017). Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells. Clinical Cancer Research. 23(15). 4280–4289. 78 indexed citations
7.
Sagawa, M., Hiroto Ohguchi, Takeshi Harada, et al.. (2017). Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma. Clinical Cancer Research. 23(17). 5225–5237. 30 indexed citations
8.
Sacco, Antonio, Aldo M. Roccaro, Dong-Dong Ma, et al.. (2016). Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model. Cancer Research. 76(2). 463–471. 41 indexed citations
9.
Amodio, Nicola, Maria Angelica Stamato, Annamaria Gullà, et al.. (2016). Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. Molecular Cancer Therapeutics. 15(6). 1364–1375. 96 indexed citations
10.
Magrangeas, Florence, Rowan Kuiper, Hervé Avet‐Loiseau, et al.. (2016). A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. Clinical Cancer Research. 22(17). 4350–4355. 30 indexed citations
11.
Zhao, Jianjun, Yiguo Hu, Jianhong Lin, et al.. (2015). Targeting the miR-221–222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. Cancer Research. 75(20). 4384–4397. 72 indexed citations
12.
Gullà, Annamaria, Maria Teresa Di Martino, Maria Eugenia Gallo Cantafio, et al.. (2015). A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Clinical Cancer Research. 22(5). 1222–1233. 97 indexed citations
13.
Zhao, Jianjun, Jianhong Lin, Di Zhu, et al.. (2014). miR-30-5p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt/β-Catenin/BCL9 Pathway. Cancer Research. 74(6). 1801–1813. 159 indexed citations
14.
Leone, Emanuela, Eugenio Morelli, Maria Teresa Di Martino, et al.. (2013). Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth. Clinical Cancer Research. 19(8). 2096–2106. 184 indexed citations
15.
Krönke, Jan, Namrata D. Udeshi, Anupama Narla, et al.. (2013). Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells. Science. 343(6168). 301–305. 1288 indexed citations breakdown →
16.
Fulciniti, Mariateresa, Samirkumar B. Amin, Puru Nanjappa, et al.. (2011). Significant Biological Role of Sp1 Transactivation in Multiple Myeloma. Clinical Cancer Research. 17(20). 6500–6509. 42 indexed citations
17.
Cirstea, Diana, Teru Hideshima, Scott J. Rodig, et al.. (2010). Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound –Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma. Molecular Cancer Therapeutics. 9(4). 963–975. 136 indexed citations
18.
Ooi, Melissa, Patrick Hayden, Vassiliki Kotoula, et al.. (2009). Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib. Clinical Cancer Research. 15(23). 7153–7160. 53 indexed citations
19.
McMillin, Douglas W., Melissa Ooi, Jake Delmore, et al.. (2009). Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235. Cancer Research. 69(14). 5835–5842. 105 indexed citations
20.
Carrasco, Daniel R., Daniel R. Carrasco, Kumar Sukhdeo, et al.. (2007). The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis. Cancer Cell. 11(4). 349–360. 311 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul G. Richardson Breakdown of academic impact, for papers by Teru Hideshima Breakdown of academic impact, for papers by Bart Barlogie Breakdown of academic impact, for papers by Michael Andreeff Breakdown of academic impact, for papers by Shaji Kumar Breakdown of academic impact, for papers by Philippe Moreau Breakdown of academic impact, for papers by Francis J. Giles Breakdown of academic impact, for papers by Bob Löwenberg Breakdown of academic impact, for papers by Elihu H. Estey Breakdown of academic impact, for papers by Angela Dispenzieri
Rankless by CCL
2026